BS_593HEWBF
Ganglioglioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Ganglioglioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Ganglioglioma
- overall_survival_months
- 18.95532194480946
- age_years
- 5.734
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.666
- INFLAMMATORY_RESPONSE+0.567
- CHOLESTEROL_HOMEOSTASIS+0.554
- TGF_BETA_SIGNALING+0.543
- IL6_JAK_STAT3_SIGNALING+0.529
- INTERFERON_GAMMA_RESPONSE+0.481
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- INTERFERON_ALPHA_RESPONSE+0.463
- COAGULATION+0.458
- ALLOGRAFT_REJECTION+0.455
Top 10 suppressed
- DNA_REPAIR-0.407
- MYC_TARGETS_V1-0.349
- MYC_TARGETS_V2-0.312
- OXIDATIVE_PHOSPHORYLATION-0.291
- WNT_BETA_CATENIN_SIGNALING-0.262
- E2F_TARGETS-0.080
- UNFOLDED_PROTEIN_RESPONSE-0.066
- SPERMATOGENESIS-0.022
- GLYCOLYSIS+0.009
- G2M_CHECKPOINT+0.021
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10900576 | — | — | 0.946 |
| 2 | BS_HQ5BJ6MW | pilocytic astrocytoma | — | 0.935 |
| 3 | BS_QRNSKFMS | pilocytic astrocytoma | — | 0.917 |
| 4 | BS_S7CZY2CH | low-grade glioma | — | 0.912 |
| 5 | EPT0509 | EPN | EPN Tumor | 0.912 |
| 6 | BS_V89HGTET | pilocytic astrocytoma | — | 0.910 |
| 7 | s0122206 | — | — | 0.907 |
| 8 | MNG1172 | — | — | 0.905 |
| 9 | SRR8518191 | — | D | 0.903 |
| 10 | BS_TK84K675 | high-grade glioma | — | 0.901 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.666 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.567 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.554 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.543 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.529 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.481 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.463 | Inavolisib | — uncovered |
| COAGULATION | 0.458 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.455 | Idelalisib | — uncovered |
| COMPLEMENT | 0.420 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.412 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.404 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.403 | Inavolisib | — uncovered |
| APOPTOSIS | 0.385 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.376 | Inavolisib | — uncovered |
| MYOGENESIS | 0.359 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.291 | Idelalisib | — uncovered |
| HYPOXIA | 0.279 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.275 | Idelalisib | — uncovered |